- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00694655
Human Immune Responses to Yellow Fever Vaccination
Study Overview
Detailed Description
Yellow fever is a viral disease that is transmitted to humans through the bite of an infected mosquito. Yellow fever is a life-threatening infection that can result in hepatitis, renal failure and coagulation abnormalities, and in severe cases, death. Yellow fever was a major public health threat in the colonial United States in the 18th and 19th centuries.
Yellow fever is endemic in over 40 countries, and approximately 125 countries require proof of vaccination for entry by travelers at risk. An estimated 200,000 cases of yellow fever occur annually in South America and Africa, making it an important vaccine-preventable disease among travelers to endemic areas. Yellow fever can be prevented by vaccination with the Yellow Fever Vaccine. Currently, the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend yellow fever vaccination for persons ≥ 9 months of age who are traveling to or living in a yellow fever endemic area.
The Yellow Fever Vaccine is considered to be one of the safest and most effective viral vaccines ever developed. Yellow Fever Vaccine is known to stimulate broad-spectrum immune responses, including cytotoxic T cells, and Th1 and Th2 responses, as well as neutralizing antibody titers that can persist for up to 30 years, after a single vaccination. Despite the great success of this empiric vaccine, there has been relatively little understanding of the mechanisms by which Yellow Fever Vaccine induces such robust protective immune responses. The researchers hope to apply the best contemporary methods in immunology, genomics, and proteomics to characterize in detail a successful immune response to Yellow Fever vaccination. This characterization should identify new immunologic predictors that could serve as surrogates for future vaccine efficacy studies. In addition, these findings could guide development of a safer yellow fever vaccine (or the derivation of safer alternative vaccination regimens using the currently available vaccine).
This study plans to recruit both travelers to yellow fever endemic areas as well as non-travelers for participation. Healthy participants will be enrolled into four study arms. Arm enrollment is determined by Human Leukocyte Antigen (HLA) type, current needs of the lab and/or willingness to participate in sampling procedures. All participants receive Yellow Fever Vaccine on Day 0 at the FDA-approved dose and route of administration. Post-vaccination procedures are determined by arm assignment. Participants will be followed for up to 360 days post-vaccination.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Srilatha Edupuganti, MD, MPH
- Phone Number: 404-712-1370
- Email: sedupug@emory.edu
Study Locations
-
-
Georgia
-
Decatur, Georgia, United States, 30030
- Recruiting
- The Hope Clinic of the Emory Vaccine Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to understand and give informed consent
- Age 18-45 years
- Participant agrees not to take any live vaccines 30 days before or after (14 days for inactivated, including coronavirus disease 2019 (COVID-19) vaccination) yellow fever vaccination
- Women of child bearing potential must agree to use effective birth control throughout the duration of the study. A negative urine pregnancy test must be documented prior to vaccination. Participants who have a history of surgical sterilization or post-menopausal status >1 year, are not required to have a pregnancy test.
Exclusion Criteria:
- Prior receipt of a yellow fever vaccine
- Lived in a country/area which is endemic for yellow fever
- Travel to country/area which is endemic for yellow fever. Subject to investigator discretion
- History of previous yellow fever, West Nile, Dengue, St. Louis encephalitis, Japanese encephalitis vaccination or infection
- Any history of allergy to eggs, chicken or gelatin or to any previous vaccine
- A history of a medical condition resulting in impaired immunity (such as HIV infection, cancer, particularly leukemia, lymphoma, use of immunosuppressive or antineoplastic drugs or X-ray treatment). Persons with previous skin cancers or cured non-lymphatic tumors are not excluded from the study
- History of HIV infection
- Active Hepatitis B or Hepatitis C infection
- COVID-19 infection in the last 30 days. Symptoms of COVID-19 must be completely resolved before yellow fever vaccine receipt.
- History of any chronic medical conditions that are considered progressive (ex, diabetes, heart disease, lung disease, liver disease, kidney disease, gastrointestinal diseases and uncontrolled hypertension). Use of systemic immunosuppressive medications (ex, prednisone) for 2 weeks or more in the past 3 months
- History of excessive alcohol consumption, drug abuse, psychiatric conditions, social conditions or occupational conditions that in the opinion of the investigator would preclude compliance with the trial
- Thymus gland problems (such as myasthenia gravis, DiGeorge syndrome, thymoma) or removal of thymus gland or history of autoimmune disorder
- Recipient of a blood products or immune globulin product within 42 days of the vaccination visit. Participants who received COVID monoclonal antibodies (mAbs) for treatment are not excluded
- Pregnant women and nursing mothers or women who are planning to become pregnant for the duration of the study
- Any condition in the opinion of the investigator that would interfere with the proper conduct of the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HLA-A202+: Yellow Fever Vaccine and Post-vaccination Blood Draws
HLA-A202+ participants receiving Yellow Fever Vaccine plus post-vaccination blood draws.
|
Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.
Other Names:
|
Experimental: HLA-A202+: Yellow Fever Vaccine, Post-vaccination Blood Draws and Leukapheresis
HLA-A202+ participants receiving Yellow Fever Vaccine plus post-vaccination blood draws and leukapheresis.
|
Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.
Other Names:
|
Experimental: HLA-A202+: Yellow Fever Vaccine, Post-vaccination Blood Draws and Fine Needle Aspirate
HLA-A202+ participants receiving Yellow Fever Vaccine plus post-vaccination blood draws and fine needle aspirate.
|
Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.
Other Names:
|
Experimental: HLA-A202-: Yellow Fever Vaccine and Post-vaccination Blood Draws
HLA-A202- participants receiving Yellow Fever Vaccine plus post-vaccination blood draws.
|
Participants receive Yellow Fever Vaccine, at the FDA approved dose and route of administration.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Magnitude of Yellow Fever Virus (YFV) specific T Cell Responses
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
The characterization of Yellow Fever Vaccine specific adaptive immune response will be examined as the magnitude of YFV-specific T cell responses.
The schedule of follow up visits depends on if participants test positive for human leukocyte antigen (HLA) A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Quality of YFV-specific T Cell Responses
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
The characterization of Yellow Fever Vaccine specific adaptive immune response will be examined as the quality of YFV-specific T cell responses.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Magnitude of YFV-specific Antibody Secreting Cells
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
The characterization of Yellow Fever Vaccine specific adaptive immune response will be examined as the magnitude of YFV-specific antibody secreting cells.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Quality of YFV-specific Antibody Secreting Cells
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
The characterization of Yellow Fever Vaccine specific adaptive immune response will be examined as the quality of YFV-specific antibody secreting cells.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Magnitude of YFV-specific Memory B Cells
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
The characterization of yellow fever vaccine (YFV-17D) specific adaptive immune response will be examined as the magnitude of YFV-specific memory B cells.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Quantity of YFV-specific Memory B Cells
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
The characterization of Yellow Fever Vaccine specific adaptive immune response will be examined as the quantity of YFV-specific memory B cells.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Peripheral Blood Mononuclear Cell (PBMC) Cytokines
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
To determine the signatures of innate immune responses, cytokines on peripheral blood mononuclear cells (PBMCs) will be examined.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in PBMC Chemokines
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
To determine the signatures of innate immune responses, chemokines on PBMCs will be examined.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in PBMC Dendritic Cells
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
To determine the signatures of innate immune responses, dendritic cells on PBMCs will be examined.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in PBMC Gene Expression
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
To determine the signatures of innate immune responses, microarray analyses for gene expression on PBMCs will be performed.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Characterization of Epstein-Barr Virus (EBV)
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Characterization of EBV cluster of differentiation 8 (CD8) T cells will be performed.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Phenotypic Analysis of Epstein-Barr Virus (EBV)
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Phenotypic analysis of EBV CD8 T cells will be performed.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Characterization of Cytomegalovirus (CMV)
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Characterization of CMV CD8 T cells will be performed.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Phenotypic Analysis of Cytomegalovirus (CMV)
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Phenotypic analysis of CMV CD8 T cells will be performed.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Characterization of YFV
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Characterization of YFV CD8 T cells will be performed.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Change in Phenotypic Analysis of YFV
Time Frame: Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Phenotypic analysis of YFV CD8 T cells will be performed.
The schedule of follow up visits depends on if participants test positive for HLA-A202 and the different immune system responses that the study team is examining at the time when each participant enrolls.
|
Day 0 (day of vaccination), Day 3, Day 7, Day 14, Day 21, Day 28, Day 90, Day 180, Day 360
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Rafi Ahmed, PhD, Emory University
- Principal Investigator: Sri Edupuganti, MD, MPH, Emory University
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Wounds and Injuries
- Arbovirus Infections
- Vector Borne Diseases
- Flavivirus Infections
- Flaviviridae Infections
- Body Temperature Changes
- Heat Stress Disorders
- Hemorrhagic Fevers, Viral
- Hyperthermia
- Fever
- Yellow Fever
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
Other Study ID Numbers
- IRB00009560
- U19AI057266 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Yellow Fever
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingYellow Fever (Healthy Volunteers)United States
-
Emory UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Enrolling by invitationYellow Fever VaccineUnited States
-
US Army Medical Research Institute of Infectious...CompletedYellow Fever Vaccination ReactionUnited States
-
Sanofi Pasteur, a Sanofi CompanyCompletedYellow Fever (Healthy Volunteers)United States
-
University of AarhusMartin TolstrupEnrolling by invitationHealthy | Cytotoxicity | Yellow Fever Vaccination ReactionDenmark
-
Tysana Pte LtdCompletedTreatment of Acute Yellow Fever Virus InfectionSingapore
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Wellcome TrustUnknownYellow Fever VaccineBrazil
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Completed
-
Centre Hospitalier Universitaire Saint PierreActive, not recruitingHIV Infections | Yellow Fever VaccineBelgium
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Ministry of Health, BrazilActive, not recruitingImmunity | Yellow Fever VaccineBrazil
Clinical Trials on Yellow Fever Vaccine
-
EpicentreKenya Medical Research InstituteCompletedYellow FeverUganda, Kenya
-
Sanofi Pasteur, a Sanofi CompanyCompletedYellow Fever (Healthy Volunteers)United States
-
Leiden University Medical CenterThe International Society of Travel MedicineRecruiting
-
London School of Hygiene and Tropical MedicineNot yet recruitingYellow Fever
-
The Immunobiological Technology Institute (Bio-Manguinhos)...Ministry of Health, BrazilActive, not recruitingImmunity | Yellow Fever VaccineBrazil
-
University of MinnesotaNational Institute of Allergy and Infectious Diseases (NIAID)Active, not recruitingYellow FeverUnited States, Uganda
-
US Army Medical Research Institute of Infectious...CompletedYellow Fever Vaccination ReactionUnited States
-
Rockefeller UniversityNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Sanofi Pasteur, a Sanofi CompanyActive, not recruitingYellow Fever (Healthy Volunteers)United States
-
University of Sao Paulo General HospitalCompletedRheumatoid Arthritis | Systemic Sclerosis | Granulomatosis With Polyangiitis | Juvenile Idiopathic Arthritis | Sjogren's Syndrome | Takayasu Arteritis | Spondyloarthritis | Juvenile Dermatomyositis | Mixed Connective Tissue Disease | Systemic Lupus | Inflammatory MyopathyBrazil